The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome

Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is associated with slower progression of diabetic kidney disease. In this analysis, we explored the hypothesis that empagliflozin may have an impact on urinary peptides associated with chronic kidney disease (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherney, David, Perkins, Bruce A., Lytvyn, Yuliya, Heerspink, Hiddo, Rodríguez-Ortiz, María E., Mischak, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662219/
https://www.ncbi.nlm.nih.gov/pubmed/29084249
http://dx.doi.org/10.1371/journal.pone.0186910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662219/
https://www.ncbi.nlm.nih.gov/pubmed/29084249
http://dx.doi.org/10.1371/journal.pone.0186910

Ejemplares similares